News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TaiGen Biotechnology Reports Phase IIa Data for TG-0054 at the 2013 American Society of Hematology Annual Meeting



10/30/2013 6:55:02 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and 

post your resume.

TAIPEI, Oct. 29, 2013 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced the results from the US Phase IIa trial of TG-0054, a CXC chemokine receptor 4 (CXCR4) antagonist, in stem cell transplantation will be presented in an Oral Session at the 55th ASH Annual Meeting and Exposition (December 7-10, 2013) in New Orleans, LA, U.S.A.

Presentation details:

Title: Rapid Mobilization Of CD34+ Stem Cells With TG-0054, a Novel CXC Chemokine Receptor 4 (CXCR4) Antagonist
Session Name: 711. Cell Collection and Processing II
Session Date: Tuesday, December 10, 2013
Session Time: 7:30 AM - 9:00 AM
Presentation Time: 8:30 AM
Room: Ernest N. Morial Convention Center, Riverside Rooms - R02-R03

In addition to the presentation, the abstract will also be published online in the November 15, 2013 supplemental volume of the journal, Blood.

About TG-0054

TG-0054, also known as burixafor, is a novel, potent and selective chemokine receptor antagonist. TG-0054 rapidly mobilizes stem cells and progenitor cells from the bone marrow into peripheral circulation. TG-0054 has already completed Phase 1 study in healthy volunteers in the US. In addition to stem cell transplantation, other potential indications include chemosensitization and ischemic diseases.

About TaiGen Biotechnology

TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, mainland China. In addition to TG-0054, TaiGen has two other NCEs in development: Nemonoxacin (oral formulation) has completed Phase 3 trials for community-acquired pneumonia and NDA submitted to regulatory authorities in mainland China and Taiwan; and TG-2349 is a pan-genotypic NS3/4A protease inhibitor currently in Phase 1/2a trials in the US.

For more information please contact:
Peter W. Tsao, PhD, Vice President of Business Development
Tel: +886-2-8177-7072 ext 1705
ptsao@taigenbiotech.com.tw

PJ (Joe) Hsueh, Vice President of Operations
Tel. +886-2-8177-7072 ext 1704
pjhsueh@taigenbiotech.com.tw

SOURCE Taigen Biotechnology



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES